Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2026-03-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. It details changes to the number of recipients and the number of shares granted due to employee turnover. Since this document does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes), and it is a formal regulatory disclosure filed with the financial authorities, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate disclosures.
2026-03-11 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including cancellations and adjustments to the total number of shares. In the context of financial filings, reports regarding stock options, equity compensation, and capital structure changes that do not fit into specific categories like 'Director's Dealing' or 'Share Issue' are classified as Regulatory Filings (RNS) as they represent official corporate disclosures to the financial authorities.
2026-03-11 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically a '정정신고' (Amendment Report). It details changes to previously granted stock options due to employee resignations. In the context of financial filings, announcements regarding stock option grants, amendments, or capital structure changes that do not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital) are classified as general regulatory filings.
2026-03-11 Korean
전환가액의조정
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing from a Korean company (TiumBio) regarding the adjustment of the conversion price of convertible bonds. This type of disclosure, which details changes to the terms of financial instruments (specifically conversion prices due to market price fluctuations), falls under capital structure and financing updates. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most appropriate category for adjustments to convertible debt terms.
2026-02-23 Korean
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is an official announcement regarding the scheduling and details of an Investor Relations (IR) meeting (기업설명회). It provides the date, time, location, and purpose of the event. Since this is an announcement of an upcoming event rather than the presentation slides themselves, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a formal corporate disclosure of an event.
2026-01-30 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal notice of the record date for shareholder rights. Given its nature as a regulatory notification regarding meeting preparation, it falls under the general regulatory filing category.
2025-12-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.